📊 PBH Key Takeaways
Is Prestige Consumer Healthcare Inc. (PBH) a Good Investment?
PBH demonstrates exceptional operational efficiency with 55.7% gross margins, 29.0% operating margins, and remarkable free cash flow generation (25.9% FCF margin). The ultra-strong balance sheet (3.11x current ratio, 0.56x debt/equity, 130x interest coverage) provides substantial financial stability. However, the extraordinary 2488.7% revenue surge coupled with only 2.5% net income growth signals a major acquisition with material integration risks, execution uncertainty, and concerning ROE/ROA metrics suggesting asset quality issues.
Why Buy Prestige Consumer Healthcare Inc. Stock? PBH Key Strengths
- Exceptional free cash flow generation (208.8M annually with minimal 6.0M CapEx) indicating highly capital-efficient business model
- Outstanding balance sheet strength with 3.11x current ratio, 0.56x debt/equity ratio, and 130x interest coverage providing significant financial flexibility
- Industry-leading profitability margins (55.7% gross, 29.0% operating, 16.9% net) demonstrating operational excellence and pricing power
PBH Stock Risks: Prestige Consumer Healthcare Inc. Investment Risks
- Massive 2488.7% revenue growth combined with only 2.5% net income growth indicates acquisition-driven topline expansion with integration costs, margin compression, or underperforming acquired assets
- Low return metrics (7.5% ROE, 3.9% ROA) despite strong profitability margins suggest significant goodwill impairment risk or asset utilization challenges from recent acquisition
- Modest cash position (62.4M) relative to 1.0B long-term debt and 3.5B asset base creates refinancing risk if integration generates unexpected cash needs
Key Metrics to Watch
- Organic revenue growth rate and acquisition integration progress (separating organic from acquisition-driven growth)
- Net income and operating margin trajectory through acquisition synergy realization
- Return on equity and return on assets improvement as goodwill is absorbed and acquired assets mature
Prestige Consumer Healthcare Inc. (PBH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 25.9% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 3.11x current ratio provides a solid financial cushion.
PBH Profit Margin, ROE & Profitability Analysis
PBH vs Healthcare Sector: How Prestige Consumer Healthcare Inc. Compares
How Prestige Consumer Healthcare Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Prestige Consumer Healthcare Inc. Stock Overvalued? PBH Valuation Analysis 2026
Based on fundamental analysis, Prestige Consumer Healthcare Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Prestige Consumer Healthcare Inc. Balance Sheet: PBH Debt, Cash & Liquidity
PBH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Prestige Consumer Healthcare Inc.'s revenue has grown significantly by 17% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.65 indicates the company is currently unprofitable.
PBH Revenue Growth, EPS Growth & YoY Performance
PBH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $283.4M | $46.7M | $0.97 |
| Q2 2026 | $274.1M | $42.2M | $0.86 |
| Q1 2026 | $249.5M | $47.5M | $0.95 |
| Q3 2025 | $282.7M | $53.0M | $1.06 |
| Q2 2025 | $283.8M | $53.6M | $1.07 |
| Q1 2025 | $267.1M | $49.1M | $0.98 |
| Q3 2024 | $275.5M | $52.0M | $1.04 |
| Q2 2024 | $286.3M | $51.0M | $1.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Prestige Consumer Healthcare Inc. Dividends, Buybacks & Capital Allocation
PBH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Prestige Consumer Healthcare Inc. (CIK: 0001295947)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PBH
What is the AI rating for PBH?
Prestige Consumer Healthcare Inc. (PBH) has an AI rating of BUY with 65% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PBH's key strengths?
Claude: Exceptional free cash flow generation (208.8M annually with minimal 6.0M CapEx) indicating highly capital-efficient business model. Outstanding balance sheet strength with 3.11x current ratio, 0.56x debt/equity ratio, and 130x interest coverage providing significant financial flexibility.
What are the risks of investing in PBH?
Claude: Massive 2488.7% revenue growth combined with only 2.5% net income growth indicates acquisition-driven topline expansion with integration costs, margin compression, or underperforming acquired assets. Low return metrics (7.5% ROE, 3.9% ROA) despite strong profitability margins suggest significant goodwill impairment risk or asset utilization challenges from recent acquisition.
What is PBH's revenue and growth?
Prestige Consumer Healthcare Inc. reported revenue of $807.1M.
Does PBH pay dividends?
Prestige Consumer Healthcare Inc. does not currently pay dividends.
Where can I find PBH SEC filings?
Official SEC filings for Prestige Consumer Healthcare Inc. (CIK: 0001295947) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PBH's EPS?
Prestige Consumer Healthcare Inc. has a diluted EPS of $2.78.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PBH a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Prestige Consumer Healthcare Inc. has a BUY rating with 65% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is PBH stock overvalued or undervalued?
Valuation metrics for PBH: ROE of 7.5% (sector avg: 15%), net margin of 16.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PBH stock in 2026?
Our dual AI analysis gives Prestige Consumer Healthcare Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is PBH's free cash flow?
Prestige Consumer Healthcare Inc.'s operating cash flow is $214.8M, with capital expenditures of $6.0M. FCF margin is 25.9%.
How does PBH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 16.9% (avg: 12%), ROE 7.5% (avg: 15%), current ratio 3.11 (avg: 2).